Who experiences more lurbinectedin side effects?
Patients with small cell lung cancer (SCLC), the primary indication for lurbinectedin (Zepzelca), face common side effects like fatigue, nausea, decreased appetite, pneumonia, and myelosuppression regardless of demographics. No unique side effects target specific racial or ethnic groups, but older adults (over 65) report higher rates of serious adverse events, including cytopenias and infections, during clinical trials.[1]
How does liver impairment affect risk?
Lurbinectedin requires dose adjustments or avoidance in patients with moderate to severe liver dysfunction. Those with bilirubin above the upper limit of normal or AST/ALT over three times the limit should not receive it, as it increases toxicity risks like hepatotoxicity.[1][2]
What about kidney problems?
No specific dose adjustments for renal impairment, but caution applies in end-stage renal disease due to limited data. Neutropenia and anemia risks remain elevated across kidney function levels.[1]
Patients with low blood counts or bone marrow issues
Prior bone marrow suppression heightens myelosuppression risk, the most frequent serious side effect (58% incidence). Active or recent chemotherapy patients need blood count monitoring before each dose to avoid severe neutropenia (37% grade 3/4).[1][2]
Impact of age, performance status, or prior treatments
Patients aged 75+ or with poor ECOG performance status (2-4) show increased severe adverse events (up to 80% incidence). Those pretreated with platinum-based therapy, common in relapsed SCLC, experience amplified cytopenias.[1]
Drug interactions that worsen side effects
Combining with strong CYP3A inhibitors (e.g., ketoconazole) raises lurbinectedin exposure, boosting toxicity; avoid or reduce dose. QT-prolonging drugs increase arrhythmia risk.[2]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/
[2]: FDA label for Zepzelca, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf